Immunotherapy (Checkpoint Inhibitor)

28 molecules in this therapeutic area. Open any product for its details, or send an inquiry directly.

Connect With Us

Immunotherapy (Checkpoint Inhibitor) (28)

Quick filters: Solid Tumour Hematologic Both Name A-Z Name Z-A

Therapeutic Areas

Sort by

Molecule	Drug Class / Mechanism	Oncology Type
Pembrolizumab	Anti-PD-1 mAb	Both (Solid & Hematologic)
Molecule Pembrolizumab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Nivolumab	Anti-PD-1 mAb	Both (Solid & Hematologic)
Molecule Nivolumab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Durvalumab	Anti-PD-L1 mAb	Solid Tumour
Molecule Durvalumab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Solid Tumour Drug Class / Mechanism Anti-PD-L1 mAb
Atezolizumab	Anti-PD-L1 mAb	Solid Tumour
Molecule Atezolizumab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Solid Tumour Drug Class / Mechanism Anti-PD-L1 mAb
Ipilimumab	Anti-CTLA-4 mAb	Solid Tumour
Molecule Ipilimumab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Solid Tumour Drug Class / Mechanism Anti-CTLA-4 mAb
Relatlimab	Anti-LAG-3 mAb	Solid Tumour
Molecule Relatlimab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Solid Tumour Drug Class / Mechanism Anti-LAG-3 mAb
Tremelimumab	Anti-CTLA-4 mAb	Solid Tumour
Molecule Tremelimumab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Solid Tumour Drug Class / Mechanism Anti-CTLA-4 mAb
Adebrelimab	Anti-PD-1 mAb	Both (Solid & Hematologic)
Molecule Adebrelimab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Avelumab	Anti-PD-L1 mAb	Solid Tumour
Molecule Avelumab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Solid Tumour Drug Class / Mechanism Anti-PD-L1 mAb
Balstilimab	Anti-PD-1 mAb	Both (Solid & Hematologic)
Molecule Balstilimab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Botensilimab	Anti-CTLA-4 mAb	Solid Tumour
Molecule Botensilimab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Solid Tumour Drug Class / Mechanism Anti-CTLA-4 mAb
Camrelizumab	Anti-PD-1 mAb	Both (Solid & Hematologic)
Molecule Camrelizumab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb

Pembrolizumab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Nivolumab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Durvalumab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Solid Tumour Drug Class / Mechanism Anti-PD-L1 mAb
Atezolizumab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Solid Tumour Drug Class / Mechanism Anti-PD-L1 mAb
Ipilimumab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Solid Tumour Drug Class / Mechanism Anti-CTLA-4 mAb
Relatlimab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Solid Tumour Drug Class / Mechanism Anti-LAG-3 mAb
Tremelimumab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Solid Tumour Drug Class / Mechanism Anti-CTLA-4 mAb
Adebrelimab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Avelumab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Solid Tumour Drug Class / Mechanism Anti-PD-L1 mAb
Balstilimab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Botensilimab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Solid Tumour Drug Class / Mechanism Anti-CTLA-4 mAb
Camrelizumab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb

‹ 1 2 3 ›

Product Range

Company

Global Network

Immunotherapy (Checkpoint Inhibitor)

Immunotherapy (Checkpoint Inhibitor) (28)

Pembrolizumab

Nivolumab

Durvalumab

Atezolizumab

Ipilimumab

Relatlimab

Tremelimumab

Adebrelimab

Avelumab

Balstilimab

Botensilimab

Camrelizumab

Pembrolizumab

Nivolumab

Durvalumab

Atezolizumab

Ipilimumab

Relatlimab

Tremelimumab

Adebrelimab

Avelumab

Balstilimab

Botensilimab

Camrelizumab